BRAF and melanoma: It has been observed that BRAFV600 mutations often co-occur with NF1 deletion, and that these mutations can signal as monomer and dimers when NF1 loss present.339 Consequently, in BRAFnonV600-mutant melanomas with co-occurring NF1 loss-of-function mutations, the combination of BRAFi targeting both monomeric and dimeric BRAF, along with MEK inhibition, has been shown to significantly reduce cell viability in vitro and tumor growth in vivo.